CD4 and type 1 diabetes mellitus: When using an SI>3, we found a larger number of individuals with type 1 diabetes with a CD4+ response to oxPTM-INSP-6 derivatives compared with control participants (66.7% vs 27.3%; p=0.039), while response to Nt-INSP-4 and oxPTM-INSP-3 was similar between type 1 diabetic and control participants (Nt-INSP-4: 66.7% vs 45.5%; oxPTM-INSP-3: 22.2% vs 9.1%) (ESM Table 4).